Related Experiment Video
Updated: Sep 3, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Recent Advances in Immunotherapy for the Treatment of Malignant Melanoma
Hardeep Singh Tuli1, Katrin Sak2, Ashif Iqubal3
1Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, 133 207, Haryana, India.
Abstract:
Malignant melanoma is one of the most worrisome malignancies due to its fast dissemination and early formation of metastases in multiple sites throughout the body. Despite the intensive efforts made in the last decades, the use of standard therapeutic strategies, including chemotherapy and radiotherapy, has not led to a substantial improvement in clinical outcomes, mainly because of the intrinsic resistance of melanomas to these treatment modalities. Therefore, in recent years, numerous studies have focused on the possibility of boosting the clinical responses of melanoma patients by using novel immunotherapeutic agents. In this review article, a comprehensive survey is presented about the approved immunotherapeutic drugs and their action mechanisms, besides describing the agents that are currently still in clinical trials. Moreover, the combination of immunotherapeutic drugs with conventional approaches, i.e., radiotherapy, chemotherapy, and targeted therapy, is another focal point of this review, providing valuable input for further elaboration of the best treatment regimens to prolong survival and improve the quality of life of melanoma patients.
Insights
Malignant melanoma treatments are improving with novel immunotherapies. This review covers approved and investigational immunotherapeutic drugs and their combinations with traditional therapies to enhance melanoma patient outcomes.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Malignant melanoma presents significant challenges due to rapid metastasis and resistance to conventional treatments like chemotherapy and radiotherapy.
- Despite decades of research, standard therapies offer limited improvement in clinical outcomes for melanoma patients.
Purpose of the Study:
- To provide a comprehensive review of immunotherapeutic agents for malignant melanoma.
- To discuss the mechanisms of action for approved and investigational immunotherapies.
- To explore combinations of immunotherapy with conventional treatments to improve patient survival and quality of life.
Main Methods:
- Literature review of approved immunotherapeutic drugs.
- Analysis of immunotherapeutic agents currently in clinical trials.
- Examination of combination strategies involving immunotherapy and conventional therapies (radiotherapy, chemotherapy, targeted therapy).
Main Results:
- Overview of established immunotherapeutic drugs and their mechanisms.
- Identification of emerging immunotherapeutic agents under investigation.
- Discussion of synergistic effects when combining immunotherapies with other treatment modalities.
Conclusions:
- Immunotherapy represents a promising frontier in malignant melanoma treatment.
- Combination strategies hold potential for optimizing therapeutic regimens.
- Further research into novel immunotherapies and combination approaches is crucial for advancing melanoma care.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...